Skip to content
drillr.ai
Sign up

VNDA

Vanda Pharmaceuticals Inc.

NASDAQ · Healthcare · Biotechnology · US

$4.09
+1.49%
Ask drillr

  • Oct 14, 2026, 21:40 UTC

    Vanda Pharmaceuticals Inc. put its anxiety-drug program on hold.

    Source:

  • Oct 14, 2026, 21:00 UTC

    Vanda Pharmaceuticals reported that its Phase III Study 3201 of VQW-765 for on-demand treatment of acute anxiety in adults with social anxiety disorder did not meet its primary endpoint.

    Source:

  • Sep 29, 2026, 22:45 UTC

    Vanda Pharmaceuticals announced positive topline Phase III results for HETLIOZ (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder, meeting its primary endpoint.

    Source:

  • Sep 21, 2026, 20:15 UTC

    AnaptysBio, Inc. reported its financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update.

    Source:

  • Sep 6, 2026, 02:56 UTC

    Vanda Pharmaceuticals Inc.'s Board of Directors declared a dividend distribution of one Right for each outstanding share of Common Stock to stockholders of record as of April 29, 2024, with each Right entitling the holder to purchase one one-thousandth of a share of Series A Junior Participating Preferred Stock at an exercise price of $25.00.

  • Aug 24, 2026, 11:00 UTC

    Vanda Pharmaceuticals announced that the European Commission granted Orphan Designation to its investigational drug imsidolimab for the treatment of Generalized Pustular Psoriasis, based on a positive opinion from the EMA's Committee for Orphan Medicinal Products.

    Source:

  • Aug 5, 2026, 20:01 UTC

    Vanda Pharmaceuticals announced that NEREUS for prevention of vomiting induced by motion became commercially available in Q2 2026.

    Source:

  • Aug 5, 2026, 20:01 UTC

    Vanda Pharmaceuticals reported second quarter 2026 financial results, with Fanapt net product sales up 23% to $36.0 million and total prescriptions up 31%.

    Source:

  • Jul 15, 2026, 20:30 UTC

    Vanda Pharmaceuticals announced that its NEREUS (tradipitant) will sponsor the No. 47 entry in the NTT IndyCar Series with Rahal Letterman Lanigan Racing.

    Source:

  • Jul 7, 2026, 20:30 UTC

    The FDA granted Rare Pediatric Disease Designation to Vanda Pharmaceuticals' investigational therapy VCA-894A for Charcot-Marie-Tooth disease type 2S.

    Source: